From GlobeNewswire:

Theriva Biologics, Inc. will be participating in the B. Riley Securities Oncology Conference on January 18, 2024, at 9:30 a.m. ET. The company focuses on developing treatments for cancer and related diseases in underserved areas and is currently working on proprietary therapies, including adenoviral oncolytic therapies for multiple applications. For more information about the company, visit www.therivabio.com.

The company’s main candidates are VCN-01, an adenoviral therapy designed to selectively replicate within tumor cells and degrade the tumor stromal barrier, SYN-004 (ribaxamase) designed to prevent antibiotic-induced microbiome damage, and SYN-020, an oral formulation of intestinal alkaline phosphatase. These therapies have the potential to address various gastrointestinal diseases and improve treatment access for cancer patients. For more information, visit www.therivabio.com. For investor relations, contact Chris Calabrese at [email protected] or 917-680-5608.

Theriva Biologics, Inc. is a clinical-stage biotech company focused on developing treatments for cancer and related diseases. The company is currently working on developing proprietary adenoviral oncolytic therapies, including VCN-01, SYN-004 (ribaxamase), and SYN-020, to address the treatment of cancer and gastrointestinal diseases. For the full update on the company’s progress, check out www.therivabio.com. For investor relations, contact Chris Calabrese at [email protected] or 917-680-5608.

Through its proprietary adenoviral oncolytic therapies, Theriva Biologics aims to offer new and better treatment options for cancer and gastrointestinal diseases. These therapies have shown potential to selectively replicate within tumor cells, degrade tumor stromal barriers, and prevent antibiotic-induced microbiome damage. The company’s main candidates include VCN-01, SYN-004 (ribaxamase), and SYN-020, with the aim of improving patient outcomes. Visit www.therivabio.com for more details and investor relations contact information.



Read more: Theriva Biologics participará en la Conferencia Anual de